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Abstract 
Background: Graft-versus-host disease (GVHD) after liver and kidney transplantation has high mortality and causes 
diagnostic challenges. This study aims to describe the cytokine and human leukocyte antigen (HLA) profile in the 
GVHD after liver and kidney transplantation.
Methods: A high-throughput detection kit was applied and altogether 18 different cytokines were tested simulta-
neously. GVHD patients included 23 post-liver transplantation patients; 22 post-renal transplantation patients; The 
control patients include 22 hepatocellular carcinoma (HCC) patients without transplantation and 20 healthy controls. 
Their HLA characters were compared.
Results: The full spectrum of cytokines was present. The inflammatory markers were activated significantly in liver 
transplantation. The level of inflammatory markers in liver transplantation was higher than that in renal transplanta-
tion, HCC or healthy controls. GVHD was associated with the HLA characters; HLA characters are involved in liver 
GVHD occurrence and act as risk factors.
Conclusion: Our findings confirmed that the inflammatory cytokines play a pathogenic role in GVHD and can be 
used as early diagnostic markers. The HLA mismatch acts as a risk factor in liver transplantation to predict GVHD 
occurrence.
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Background
Hepatocellular carcinoma (HCC) is the second lead-
ing cause of cancer-related death in the world [1, 2] 
and China accounts for almost half of HCC cases [2]. 
The liver transplantation is the curative treatment for 
HCC but post-transplantation graft-versus-host dis-
ease (GVHD) has caused mortality [3, 4]. The cytokine 
and HLA profile of GVHD can help understand the 
inflammatory background and the risk factors [5, 6]. 
The full profile of cytokine in the cytokine storms post 
GVHD is still lacking. In this study, we present a high-
throughput cytokine exam for GVHD after liver and 




Altogether, 87 patients were included: 23 HCC patients 
with liver transplantation (LT); 22 renal transplanta-
tion (RT); 22 HCC without transplantation (HCC); 
and 20 healthy controls (control). Patients underwent 
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Measurement of cytokines by multiplex immunoassay
The multiple cytokines were measured by Multiplex 
Immunoassay Kit (Affymetrix, CA, USA). Briefly, 25 μL 
serum and standards were incubated with pre-mixed 
beads coated with antibodies. After washing, plates were 
incubated with the detection antibody and the reaction 
revealed with streptavidin–phycoerythrin. The beads 
were analyzed on a Luminex system (Bio-Rad, USA) for 
the concentration of the following 18 cytokines: IL-10, 
IL-17A, IL-21, IL-22, IL-23, IL-27, IL-9, GM-CSF, IFN-
γ, IL-1b, IL-12, P70, IL-13, IL-18, IL-2, IL-4, IL-5, IL-6, 
TNF-α.
Pathological confirmation of the skin biopsy
The pathological slides of the biopsy were reviewed 
and the pathological figures to support the diagnosis of 
GVHD was present. The skin sample was stained and 
read by two independent pathologists. The hematoxylin–
eosin (H&E) was stained for the confirmation of GVHD.
The anti‑HLA antibody measurement
The HLA antibodies were measured by Luminex technol-
ogy (One Lambda, Inc. Canoga Park, CA, USA). Accord-
ing to the manufacturer’s manual book, HLA-specific 
antibodies were identified using immune beads coated 
with purified HLA antigens. HLA antibodies in patient’s 
serum were bound to the antigens coated on the beads. 
The complex was then stained with R-phycoerythrin-
conjugated goat anti-human IgG. The fluorescent emis-
sion of R-phycoerythrin was measured and then analyzed 
by HLA analysis software (Canoga Park, CA, USA.). All 
adjusted and normalized reactions that were above 500 
were considered positive.
Statistical analysis
The present data are expressed as mean ±  SD. For sta-
tistical comparison of values, Student’s t test was used. 
P values less than 0.05 were deemed to indicate statisti-
cal significance. The SPSS one-way analysis of variance 




The four groups are age-, sex-, and storage-time-matched. 
The typical symptoms were skin lesions. The liver func-
tion was not affected and the liver damage was not 
obvious. A nonspecific skin basal vacuolar changes, dys-
keratosis in the epidermis were found. Diarrhea was the 
most common complaints due to the absorptive function 
loss caused by lymphocyte infiltration and destruction of 
the intestinal mucosa (Table 1).
Screening of cytokines
Among all the 18 screened cytokines, three cytokines 
IL-12, IL-18 and IFN-γ showed a significant increase, and 
the diagnostic value varied from 0.5 (IL2) to 1.22 pg/mL 
(IL-18). The Luminex immunoassay measures cytokines 
in pg levels. Multiple cytokines can be tested in a single 
run by using a small volume of serum sample (Fig. 1).
HLA identification
HLA haplotype is shown in Fig.  2. There were donor–
recipient HLA-mismatching in liver-transplanted patients. 
Renal transplantation (RT) requires a strict matching, so 
there was no HLA mismatching status in any of kidney 
case in our study. All of the 22 cases of renal transplanta-
tion (Fig.  2) had no mismatches at HLA-A, HLA-B, and 
HLA-DR loci. HLA-typing showed that the liver donor 
shared a single antigen with the patient, but the donor 
was heterozygous at other loci (A2, A24, B13, B46, DR12). 
Although liver transplantation (LT) dose not require a 
strict HLA compatibility as renal transplantation. Our 
result verified that the use of the HLA-mismatching donor 
can result in the risk of developing GVHD after LT.
The pathology of skin lesion biopsy
The biopsy from skin on right thigh of GVHD patient 
was shown (Fig.  3a). The pathology showed epidermal 
atrophy, excessive keratosis and parakeratosis in the epi-
dermis (Fig. 3b) with significant dermal fibrosis and col-
lagen (Fig.  3c). The lymphocytic infiltration was seen 
but not significant (Fig.  3d). The dermal perivascular 
inflammatory cell infiltration was found invading into the 
epithelium (Fig.  3b). Diagnosis: skin squamous cell dys-
keratosis associated with dermal chronic inflammatory 
cell infiltration.
Different from kidney transplantation, which requires 
a strict donor–recipient HLA matching to improve 
long-term prognosis, liver transplantation can tolerate 
the HLA-mismatching to some degree. The incompat-
ibility between donor and recipient might inhibit the 
host immune function.  Whether HLA-B matching and 
the other HLA loci may impact long-term survival in 
liver transplantation is still debating [12, 13]. We use 
it as a risk factor rather than an absolute evaluation 
biomarker.
Discussion
There are three basic requirements formulated by Bill-
ingham in 1966 for the development of GVHD: the graft 
must contain immunologically competent cells; the 
recipient must express tissue antigens that are not pre-
sent in the transplant donor; and the recipient must be 
incapable of mounting an effective response to eliminate 
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the transplanted cells [7–9]. Our results proved that 
GVHD post liver transplantation involved HLA mis-
match and inflammatory cytokine release.
Examining the levels and interplay of cytokines can 
help to identify GVHD biomarkers and medical interven-
tion targets [10]. However, the complicated interactions 
Table 1 The clinical characteristics of patients
Liver transplantation Renal transplantation HCC Control
Number of patients 23 22 22 20
Recipient age (years) 54 ± 19 49 ± 12 58 ± 9 51 ± 21
Male/female 13/10 10/12 13/9 10/10
Time to onset (days) 253 ± 39 192 ± 51 / /
BMI 22 ± 2.1 19 ± 3.4 20 ± 2.8 23 ± 3.2
AST (U/L) 56 ± 4 61 ± 2 45 ± 4 52 ± 3
ALT (U/L) 35 ± 2 28 ± 1 31 ± 3 31 ± 2
Total bilirubin (mg/dL) 0.95 ± 0.11 0.95 ± 0.16 0.95 ± 0.23 0.95 ± 0.37
Direct bilirubin (mg/dL) 0.45 ± 0.09 0.35 ± 0.14 0.47 ± 0.15 0.30 ± 0.17
Leukocytes (mil/mm3) 9.6 ± 2.1 4.8 ± 1.7 3.6 ± 0.4 4.5 ± 1.1
Haemoglobin (g/dL) 12 ± 2 11 ± 3 10 ± 2 14 ± 2
Fig. 1 The cytokine profile measured by multiplex immunoassay. The multiple cytokines were measured by Multiplex Immunoassay Kit (Affymetrix, 
CA, USA) for the concentration of 18 cytokines (IL-10, IL-17A, IL-21, IL-22, IL-23, IL-27, IL-9, GM-CSF, IFN-γ, IL-1b, IL-12, P70, IL-13, IL-18, IL-2, IL-4, IL-5, IL-6, 
TNF-α). Among all the 18 screened cytokines, three cytokines IL-12, IL-18 and IFN-γ showed the significant increase and diagnostic value
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of cytokine network in GVHD can only be understood 
when the full cytokine profile is present [11]. Multiplex 
immune-assays can detect multiple cytokines with a 
small amount of patient’s serum (only 25 μL) with good 
parallel among different cytokines. The multiplex lumi-
nescence immunoassay can simultaneously detect anti-
body activity to 18 antigens in a single 96-well plate. The 
exam can be performed automatically in a centralized 
laboratory. The results indicate that after GVHD onset, 
an exaggerated response of cytokines IL2, IL18, IFN-γ 
may predispose to GVHD. They can be used to predict 
the occurrence of GVHD in transplant recipients. High 
levels of the three cytokines above correlated with the 
development of GVHD. The results suggest that meas-
urement of IL2, IL18 and IFN-γ is of predictive value. 
Beside IL2, IL18 and IFN-r, the baseline of other 15 
cytokines were also present (IL-10, IL-17A, IL-21, IL-22, 
IL-23, IL-27, IL-9, GM-CSF, IL-1b, IL-12P70, IL-13, IL-4, 
IL-5, IL-6, TNF-α). These results together provide a full 
cytokine profile and further substantiate the complex 
cytokine cascade that is initiated by GVHD.
Another notable finding in our study is the cytokine dif-
ference between GVHD post liver transplantation and renal 
transplantation. The GVHD and cytokine situation in liver 
transplantation and renal transplantation is quite different. 
IL2, IL18 and IFN were all lower in RT group than other 
groups. To address this difference, we have to add an addi-
tional HLA-typing experiment to explain the reason. The 
renal transplantation requires a very strict HLA matching. 
So, all renal transplantation cases were HLA-matched. The 
GVHD in renal transportation and inflammation response 
were not as high as that in liver transplantation. The strict 
HLA match in renal transplantation might be the possible 
reason. We added a typical case of LT to show its HLA-
typing. HLA-mismatching allows patient to survive in liver 
transplantation without acute rejection. But it did increase 
the risk of GVHD in long term.
The immune mechanism on GVHD involves T cells 
and B cells. However, it is becoming increasingly focused 
on host-derived molecules that result from tissue incom-
patibility, e.g., HLA-mismatching [12]. Our result showed 
that HLA contribute to the occurrence of GVHD and 
then the rejection reaction was so wide that it caused skin 
damage. An improved understanding of these pathways 
may reveal novel therapeutic targets to decrease GVHD 
and increase long-term survival.
One major risk factor for the development of GVHD 
after LT was determined: human leukocyte antigen (HLA) 
matching between the donor and the recipient; Donor–
recipient compatibility for HLA-B was identified as a 
significant risk factor for the development of GVHD. An 
accurate diagnosis of GVHD depends on histological and 
Fig. 2 HLA profile in the recipient of GVHD post liver transplantation. The HLA antibodies was measured by Luminex system and the software from 
One Lambda, Inc. HLA specific antibodies were identified using immune beads coated with purified HLA antigens (upper panel). The fluorescent 
emission of antigen–antibody complex was measured and then analyzed (lower panel). All adjusted and normalized reactions that were above 500 
were considered positive. HLA-A, B, DR were shown
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immuno-histochemical proof [13]. In our study, the path-
ological in skin include lymphocyte infiltration, basal cell 
vacuolization and the keratinocyte resembling. The dif-
ferential diagnosis excluded the bacterial, viral and fungal 
causes of gastrointestinal symptoms. Then, the patients 
were given standard treatment of increased immune 
suppression and antibody preparations. Immune sup-
pressants are a necessary right after transplant surgeries, 
preventing the rejection-caused new organ function fail-
ure. But the long term use of immune suppressants can 
cause many side effects such as infection, cancer, diabetes, 
GVHD compared to the general population. The proper 
withdrawal or minimize the use of immune suppression 
can help the immune system reconstitute itself.
Summary
Our study provides a comprehensive platform for GVHD 
diagnosis. The HLA-mismatching works as a risk fac-
tor for the physician to suspect the high possibility of 
occurrence. Cytokine profile can be used for early diag-
nosis. Skin biopsy can be used as confirmation.
Conclusion
Our findings confirmed that the inflammatory cytokines 
play a pathogenic role in GVHD and can be used as early 
diagnostic markers and future therapeutic targets. The 
HLA mismatch acts as risk factor in liver transplantation 
to predict GVHD occurrence.
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Fig. 3 The pathology of skin lesion biopsy. The biopsy from skin on the right thigh (a). The pathology showed epidermal atrophy, excessive kerato-
sis and parakeratosis in the epidermis (b) with significant dermal fibrosis and collagen (c). The lymphocytic infiltration was seen but not significant 
(d). The inflammatory cells infiltrate and invade into the epithelium (b). Diagnosis: skin squamous cell dyskeratosis associated with dermal chronic 
inflammatory cell infiltration
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